1 Transmission of Acute Respiratory Infections during Aerosol Generating Medical

2 Procedures (AGMPs): An updated review

- 3 Jenine Leal^{1,2,3,4}, Mark Hofmeister^{1,3}, Liza Mastikhina^{1,3}, John Taplin^{1,3}, Joyce Li^{1,3}, Brenlea
- 4 Farkas^{1,3}, Laura Dowsett^{1,3}, Tom Noseworthy^{1,3} and Fiona Clement^{1,3}.
- Department of Community Health Sciences, University of Calgary, Calgary, Alberta
 Canada
 - 2. Department of Microbiology, Immunology and Infectious Diseases, University of Calgary, Calgary, Alberta Canada
 - 3. O'Brien Institute for Public Health, University of Calgary, Calgary, Alberta Canada
- 10 4. Infection Prevention and Control, Alberta Health Services, Alberta Canada
- 11

7

8

9

- 12 Mark Hofmeister
- 13 3D10, 3280 Hospital Drive NW
- 14 Calgary, AB T2N 4Z6
- 15 mrhofmei@ucalgary.ca
- 16
- 17 Liza Mastikhina
- 18 3D10, 3280 Hospital Drive NW
- 19 Calgary, AB T2N 4Z6
- 20 lmastikh@ucalgary.ca
- 21
- 22 John Taplin
- 23 3D10, 3280 Hospital Drive NW
- 24 Calgary, AB T2N 4Z6
- 25 jgtaplin@ucalgary.ca
- 26 Tom Noseworthy
- 27 3D10, 3280 Hospital Drive NW
- 28 Calgary, AB T2N 4Z6
- 29 <u>tnosewor@ucalgary.ca</u>
- 30

Joyce Li 3D10, 3280 Hospital Drive NW Calgary, AB T2N 4Z6 joycli@ucalgary.ca

Brenlea Farkas 3D10, 3280 Hospital Drive NW Calgary, AB T2N 4Z6 <u>brenlea.farkas@ucalgary.ca</u>

Laura Dowsett 3D10, 3280 Hospital Drive NW Calgary, AB T2N 4Z6 <u>lelegget@ucalgary.ca</u>

Fiona Clement 3D10, 3280 Hospital Drive NW Calgary, AB T2N 4Z6 <u>fclement@ucalgary.ca</u>

- Author Contributions Statement: *Conceptualization of study*: JLeal. Methodology: JLeal,
 FClement, LDowsett, MHofmeister, LMastikhina, JTaplin, JLi, BFarkas. *Supervision*: FClement,
- 32 TNoseworthy, JLeal. *Analysis*: LDowsett, MHofmeister, LMastikhina, JTaplin, JLi, BFarkas.
- *Writing of original draft:* JLeal, LDowsett, MHofmeister, LMastikhina, JTaplin, JLi, BFarkas.
- 35 *Reviewing and editing draft:* FClement, TNoseworthy, MHofmeister, LDowsett, LMastikhina,
- 36 JTaplin, JLi, BFarkas
- 37
- 38 Acknowledgment: We would like to Dr. John Conly, the senior author of the original systematic
- 39 review for reviewing and commenting on this update.

- **Funding Statement:** The SPOR Evidence Alliance (SPOR EA) is supported by the Canadian
- 41 Institutes of Health Research (CIHR) under the Strategy for Patient-Oriented Research (SPOR)
- 42 initiative.
- 44 COVID-19 Evidence Network to support Decision-making (COVID-END) is supported by the
- 45 Canadian Institutes of Health Research (CIHR) through the Canadian 2019 Novel Coronavirus
- 46 (COVID-19) Rapid Research Funding opportunity.

Corresponding Author:

- 50 Jenine Leal, PhD
- 51 Foothills Medical Centre
- 52 801 South Tower
- 53 3031 Hospital Drive NW
- 54 Calgary, AB T2N 2T8
- 55 Cell: (403) 973-6918
- 56 Fax: (403) 944-3886
- 57 Email: jenine.leal@albertahealthservices.ca
- 59 Keywords: aerosol-generating procedures, acute respiratory infection, healthcare worker

82 83 **1 ABSTRACT**

84

85 **Objectives**: To review the literature from 2011 until March 31st, 2020 to identify the risk of

- 86 transmission of ARIs to healthcare workers caring for patients undergoing AGMPs compared
- 87 with the risk of transmission when caring for patients not undergoing AGMPs.

89	Results: Only two prospective cohort studies were identified meeting inclusion criteria. One
90	found that performance or assistance with AGMP during the previous week was significantly
91	associated with symptomatic influenza (adjusted OR: 2.29, 95% CI: 1.3 to 4.2). The second
92	study found that performance of AGMP was significantly associated with clinical respiratory
93	infections (RR 2.9, 95% CI 1.42-5.87, p<0.01), laboratory-confirmed virus or bacteria (RR 2.9,
94	95% CI 1.37-6.22, p=0.01), and laboratory-confirmed virus (RR 3.3, 95% CI 1.01-11.02,
95	p=0.05). Further evidence is needed regarding what constitutes an AGMP and the risk of ARI
96	transmission during presumed AGMPs. Organizations need to interpret these findings with
97	caution when establishing AGMP lists requiring airborne precautions.
98	
99 100	
101	
102	
103	
104	
105	
106	

107 2 INTRODUCTION

108

109 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pneumonia (COVID-19) was 110 first identified in December 2019 in Wuhan, China and has since spread globally. Available 111 evidence suggests the primary route of human-to-human transmission of the SARS-CoV-2 virus 112 is through large respiratory droplets and contact routes. [1, 2] This is supported by studies 113 demonstrating transmission being highest within households, [2, 3] the absence of identified 114 transmission on aircraft, [4] limited reports of significant outbreaks in staff of COVID-19 115 treatment centres not using airborne precautions and N95 respirators.[5-7] Some studies have 116 measured viral RNA in the air and air vents at enough distance from patients suggesting that 117 aerosol transmission may be possible; however, whether the viral RNA in air represents living 118 virus remains unknown.[8-13] 119 120 Certain medical procedures used in the treatment of acute respiratory infection (ARI) may 121 increase the risk of aerosol generation from a patient above that of natural processes (coughing 122 etc.).[14] The World Health Organization (WHO) and the Centers for Disease Control and 123 Prevention (CDC) have identified several potentially aerosol generating procedures, which 124 necessitate the use of airborne precautions such as N95 or higher respirators, in addition to 125 gowns, gloves and eye protection along with airborne infection isolation room. [15, 16] However, 126 there has been very limited research on which medical procedures should be considered aerosol-127 generating and the evidence defining relative risk of presumed AGMPs is insubstantial.[14, 17] 128

A systematic review on AGMPs and the associated risk of transmission of ARIs by Tran et al.
(2012) identified that some procedures potentially capable of generating aerosols were associated

131	with increased risk of SARS transmission or were a risk factor for transmission.[18] Considering
132	the COVID-19 pandemic, updated evidence is required on transmission of ARIs to HCWs due to
133	aerosolized particles.

134 **3 MAIN TEXT**

135

136 **3.1 Literature Search**

137 The search strategy by Tran et al. was updated by a research librarian to capture studies in

138 MEDLINE, Embase, Cochrane Database of Systematic Reviews, Cochrane Central Register of

139 Controlled Trials, and CINAHL published from 2011 to March 31st, 2020.[18] Terms related to

140 AGMPs were combined with relevant disease terms and searched as text words in titles and

141 abstracts and as MeSH subject headings, when applicable. The search excluded case reports,

142 animal studies, conference abstracts, editorials, and letters. The full search strategy is reported in

143 Additional File 1.

144

145 **3.2 Literature Selection**

146

147 PRIMSA guidelines were followed (Additional File 2).[19] Abstracts identified were screened

148 in duplicate and all included abstracts proceeded to full-text review. Full-text publications were

screened in duplicate with discrepancies between reviewers resolved through consensus.

150 Eligibility criteria included: 1) study population of HCWs caring for patients with ARIs,

151 including but not limited to COVID-19, SARS, MERS, influenza, 2) the intervention was the

- 152 provision of care to patients undergoing AGMPs, 3) comparator was the provision of care to
- 153 patients not undergoing AGMPs, 4) the outcome was the risk of transmission of ARIs from

154	patients to HCWs and 5) the study design was a randomized controlled trial or non-randomized
155	comparative study. Publications were excluded if they were not published in English or French.
156	
157 158	3.3 Data Extraction & Analysis
159	For all included studies, year of publication, country, study design, population, aerosolizing
160	procedure, period of evaluation, assessment of training and protective equipment, and number of
161	exposed and non-exposed cases were extracted in duplicate using standardized data extraction
162	forms. Discrepancies between reviewers during data extraction were resolved through consensus.
163	Results of these studies were narratively synthesized.
164	
165 166	3.4 Results
167	Searches of electronic databases yielded 7,299 records. The full texts of 59 records were
168	screened, of which two records met inclusion/exclusion criteria (Error! Reference source not
169	found.) (Table of excluded studies, in Additional File 3).
170	Fig 1. Flow Chart of Included Studies
171	Two prospective cohort studies were identified meeting inclusion criteria (Table 1).
173	
174	
175	
176	
177	
178	

Study; Country	Design and Setting	Period of Evaluation	Population	Assessment of Training and Protection Equipment?	Laboratory Tests
Kuster et al.[20] 2013	Prospective Cohort Acute Care Hospitals	2009 H1N1 pandemic in Toronto, Canada	563 HCW 169 non- HCW	Adherence to hand hygiene and facial protection based on recommendati ons	Hemagglutination-inhibition assay to determine antibody titers against the influenza virus A(H1N1)pdm09 strain (A/California/07/2009-like) and the 2008-09 seasonal influenza virus A(H1N1) strain (A/Brisbane/59/07
MacIntyre et al.,[21] 2014	Prospective Cohort Emergency and respiratory wards from nine hospitals	1 December 2008 to 15 January 2009 in Beijing, China	481 HCW	Hand washing, use of surgical masks or cloth masks (RR not reported), influenza vaccination	Viruses: adenoviruses, human metapneumovirus, coronavirus 229E/NL63 and OC43/HKU1, parainfluenza virus 1,2, and 3, influenza virus A and B, respiratory syncytial virus A and B, and rhinovirus A/B Bacteria: Streptococcus pneumoniae, Mycoplasma pneumoniae, B. pertussis, Legionella spp, Chlamydophilia and Haemophilus influenzae type B

179 Table 1. Characteristics of studies includ
--

180

181 The primary purpose of the study conducted in Toronto was to examine the epidemiology of 182 infection caused by influenza virus A(H1N1)pdm 09 among HCWs and other working adults in 183 Canada.[20] The authors secondarily determined risk factors for laboratory-confirmed 184 symptomatic influenza among HCWs. An AGMP was defined as any one of the following: 185 administration of nebulized therapy or humidified oxygen at >40%, use of bag-valve mask, 186 manual ventilation, non-invasive ventilation, open airway suctioning, bronchoscopy or other 187 upper airway endoscopy, tracheostomy, endotracheal intubation, cardiopulmonary resuscitation, 188 oscillatory ventilation, or any procedure that involved manipulation of open ventilatory tubing in 189 a mechanically ventilated patient, or sputum induction or other deliberate induction of 190 coughing.[20] In multivariate analysis adjusted for receipt of vaccine and dynamics of pandemic

191 waves, Kuster et al. (2013)[20] found that performance or assistance with AGMP during the
192 previous week was significantly associated with symptomatic influenza (adjusted OR: 2.29, 95%
193 CI: 1.3 to 4.2).[20]

194

195 In the second study, MacIntyre et al. (2014) prospectively studied 481 HCWs from emergency 196 and respiratory wards from nine hospitals in Beijing China. Healthcare workers were subjects of 197 a control group in a larger cluster randomized control trial (RCT) comparing fit-tested and non-198 fit tested N95 respirators to medical masks to prevent respiratory viral infection in HCWs. High 199 risk procedures were defined as: provision of nebulizer medications, suctioning, intubation, 200 AGMPs, and chest physiotherapy. [21] MacIntyre et al. (2014)[21] measured transmission of 201 clinical respiratory infections defined as: presence of two or more respiratory symptoms; or, one 202 respiratory symptom and one or more systemic symptoms. Laboratory-confirmation of viruses 203 and bacteria included are listed in Table 1. Fifty-six (11.6%) HCWs performed at least one high 204 risk procedure during the study, with the most common activity being airway suctioning (66%, 205 37/56). Using Poisson regression, MacIntyre et al. (2014)[21] found that performance of AGMP 206 was significantly associated with clinical respiratory infections (RR 2.9, 95% CI 1.42-5.87, 207 p<0.01), laboratory-confirmed virus or bacteria (RR 2.9, 95% CI 1.37-6.22, p=0.01), and 208 laboratory-confirmed virus (RR 3.3, 95% CI 1.01-11.02, p=0.05). 209

210 **3.5 Discussion**

211

Two studies were identified in this update of the systematic review conducted by Tran et al.[18]
Both additional studies concluded that the performance of AGMPs significantly increased risk of
ARI transmission to HCWs.

215

216 In both studies, there was a lack of power related to small number of cases of ARIs in the HCW 217 groups and AGMPs were combined. Hence, risk could not be attributed to individual procedures 218 as it was in the study by Tran et al. The study by Kuster et al (2013) was further limited by the 219 potential of: enrollment bias with increased participation by individuals who perceive having a 220 higher risk for influenza infection; recall bias with ill participants potentially reporting risk 221 factors more accurately than people who did not develop the illness; and a Hawthorne effect 222 whereby participants may have altered their behaviour (e.g. increased adherence to protective 223 measures) as a result of participating in the study.[20] Although the participants in the MacIntyre 224 et al. study were part of a control group of a cluster RCT, similar limitations such as recall bias 225 may persist.[21]

226

Interpretation of these findings is complicated by variation across jurisdictions in clinical care;
quantity and type of AGMPs performed, infection prevention and control (IPC) practices,
availability of personal protective equipment (PPE); type of PPE; and individual use and fit of
PPE for each procedure. In addition to these sources of variation, validity of estimates from
meta-analysis in the Tran et al. study was threatened by the very low quality of evidence
available. Given this, the interpretation and practical application of the study findings is difficult.

Despite the limited and insubstantial evidence on the types of procedures that constitute an
AGMP and the risk associated with presumed AGMPs, many organizations and medical
societies have taken a precautionary approach and adopted the full or partial list of procedures
identified by Tran et al. (2012).[1, 16, 22, 23] The Infectious Disease Society of America

238 identified that there was no direct evidence of AGMPs and rates of COVID-19 infection among 239 healthcare workers and that despite the very low quality and indirect evidence, they placed a high 240 value on avoiding serious harms to exposed health care personnel.[23] They present the CDC 241 and WHO's variable lists and rank the procedures from Tran et al. from highest odds ratio to 242 lowest, despite many of the 95% confidence intervals crossing one and not being statistically 243 significant. [23] A more transparent approach would be to present the results highlighting the 244 procedures that have consistently demonstrated higher risk (e.g. Tracheal intubation). With the 245 uncertainty and caution surrounding risk of transmission of SARS-CoV-2 among HCWs, other 246 procedures have been proposed as potential AGMPs despite limited to no studies pertaining to 247 their risk.[24-26] In our jurisdiction, a similar list of procedures was proposed by various clinical 248 groups and societies. This list was reviewed by an expert working group made up of IPC 249 physicians and professionals, workplace health and safety physicians, epidemiologists and 250 respiratory therapists. Where decisions to exclude procedures as AGMPs differed from 251 national/international clinical societies, engagement with these local groups occurred to establish 252 consensus.[27] Other jurisdictions have employed similar processes to develop lists of 253 AGMPs.[28] The result of including or excluding procedures as AGMPs using this approach will 254 differ across jurisdictions depending on IPC guidelines and procedures, perceived risk of 255 transmission and infection, and availability of PPE.

256

In the context of COVID-19, the evidence for HCW exposure through AGMPs is also limited and the generalizability of these findings to the current COVID-19 outbreak is unclear.[29] In a case control study among HCWs with acute respiratory symptoms working in the designated hospital of Wuhan University, HCW risk of developing COVID-19 was higher in areas where

AGMPs were performed (ICUs, respiratory wards, infection department and surgical
department).[30] However, this risk was nullified when exposure was stratified by specific
AGMPs (e.g. tracheal tube removal, sputum suction, fiber bronchoscopy). Additionally, HCW
risk increased substantially on these units by self reported inadequate hand hygiene
practices.[30] An epidemiological investigation was conducted of a patient diagnosed with
COVID-19 after being nursed in an open ward with 10 other patients for 35 hours and being on
high flow oxygen for 18.5 hours before being transferred to an airborne isolation room. Thirty-
two of 71 staff developed respiratory symptoms but were all negative for SARS-CoV-2.[6] In
another study, 41 HCWs were exposed to AGMPs for at least 10 minutes at a distance less than 2
metres during the care of a retrospectively diagnosed COVID-19 patient in an ICU setting.[7]
The AGMPs included endotracheal intubation, extubation, noninvasive ventilation and exposure
to aerosols in an open circuit. A majority (85%) of exposed HCWs wore surgical masks, rather
than N95 respirators, and followed standard contact and droplet precautions. None of the
exposed HCWs developed symptoms and all tests for SARS-CoV-2 were negative. [7]
3.6 Conclusion
Like the Tran et al. review, this undete finds the presence of a significant research can which is

Like the Tran et al. review, this update finds the presence of a significant research gap which is
further compounded by the lack of precision in the literature regarding the definition for
AGMPs.[22] Further evidence is needed regarding the probability and types of infections
following exposure, by type of procedure and PPE. Multidisciplinary teams should strive to use
robust epidemiologic, engineering and aerodynamics or aerobiology study designs to identify
associations between viral particles expelled and collected from aerosols generated by these
procedures with viable virus capable of infecting susceptible hosts. This would enhance the

285	transferability of lessons learnt from AGMPs, whether from SARS, H1N1 or COVID-19 and
286	prepare us for the next wave of COVID-19 or future pandemics of a respiratory nature.
287	

288 4 LIMITATIONS

290	This review has limitations given the expected rapid turnaround for completion. We were not
291	able to search the grey literature for additional publications and we did not apply the GRADE
292	assessment to the two studies. Individual AGMPs could not be delineated from the grouped
293	analysis in the studies and therefore risk could not be assigned to individual procedures. The
294	search strategy included terms and key words originally identified in the Tran et al. study;
295	however, since the search, clinical societies have proposed the inclusion of other procedures,
296	which were not included in the original search. However, many of these recommendations have
297	not been substantiated by existing evidence so we do not think we have missed a significant
298	portion of the literature.
299	
300	
301	
302	
303	
304	
305	
306	
307	
308	

309 LIST OF ABBREVIATIONS

310 311 312 313 314 315 316 317 318 319 320 321 322 323	AGMPs ARIs CDC HCWs ICUs IPC OR PPE RCT RR SARS WHO	aerosol-generating medical procedures acute respiratory infections Center for Disease Control and Prevention healthcare workers intensive care units infection prevention and control odds ratio personal protective equipment randomized control trial relative risk severe acute respiratory syndrome World Health Organization
324		
325		
326		
327		
328		
329		
330		
331		
332		
333		
334		
335		
336		
337		
338		

339 **5 DECLARATIONS**

- 340 **Ethics approval and consent to participate:** Not applicable
- 341 Availability of data and material: Not applicable. All data and material available in the
- 342 manuscript.
- 343 **Funding:** Not applicable
- 344 Acknowledgements: We would like to Dr. John Conly, the senior author of the original
- 345 systematic review for reviewing and commenting on this update.
- 346 **Consent for publication:** Not applicable
- 347 **Competing Interests:** The Authors declare that they have no competing interests.
- 348 Authors' Contributions: *Conceptualization of study*: JLeal. Methodology: JLeal, FClement,
- 349 LDowsett, MHofmeister, LMastikhina, JTaplin, JLi, BFarkas. Supervision: FClement,
- 350 TNoseworthy, JLeal. Analysis: LDowsett, MHofmeister, LMastikhina, JTaplin, JLi, BFarkas.
- 351 Writing of original draft: JLeal, LDowsett, MHofmeister, LMastikhina, JTaplin, JLi, BFarkas.
- 352 Reviewing and editing draft: FClement, TNoseworthy, MHofmeister, LDowsett, LMastikhina,
- 353 JTaplin, JLi, BFarkas
- 354
- 355
- 356
- 357
- 358
- 359
- 360
- 361
- 362
- - -
- 363

364 6 **REFERENCES**

366 367 368	1. World Health Organization. Coronavirus disease (COVID-19) technical guidance: Infection prevention and control. [Internet]. Geneva, Switzerland: World Health Organization; 2020 [Available from: <u>https://www.who.int/emergencies/diseases/novel-coronavirus-</u>
369	<u>2019/technical-guidance/infection-prevention-and-control</u> .
370	2. World Health Organization. Report of the WHO-China Joint Mission on Coronavirus
371	Disease 2019 (COVID-19). Geneva, Switzerland: World Health Organization; 2020 16-24
372	February 2020.
373 374	3. Chan JF, Yuan S, Kok KH, To KK, Chu H, Yang J, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of
375	a family cluster. Lancet. 2020;395(10223):514-23.
376	4. Schwartz KL, Murti M, Finkelstein M, Leis J, Fitzgerald-Husek A, Bourns L, et al. Lack
377	of COVID-19 transmission on an international flight2020 24 March 2020. Available from:
378	https://www.cmaj.ca/content/192/7/E171/tab-e-letters#lack-of-covid-19-transmission-on-an-
379	international-flight.
380	5. Canova V, Lederer Schlapfer H, Piso RJ, Droll A, Fenner L, Hoffmann T, et al.
381	Transmission risk of SARS-CoV-2 to healthcare workers -observational results of a primary care
382	hospital contact tracing. Swiss Med Wkly. 2020;150:w20257.
383	6. Wong SC, Kwong RT, Wu TC, Chan JWM, Chu MY, Lee SY, et al. Risk of nosocomial
384	transmission of coronavirus disease 2019: an experience in a general ward setting in Hong Kong.
385	J Hosp Infect. 2020.
386	7. Ng K, Poon BH, Kiat Puar TH, Shan Quah JL, Loh WJ, Wong YJ, et al. COVID-19 and
387	the Risk to Health Care Workers: A Case Report. Ann Intern Med. 2020.
388	8. Santarpia JL, Rivera DN, Herrara V, Morwitzer MJ, Creager H, Santarpia GW, et al.
389	Transmission Potential of SARS-CoV-2 in Viral Shedding Observed at the University of
390	Nebraska Medical Center. medRxiv. [preprint]. In press 2020.
391	9. Liu Y, Ning Z, Chen Y, Guo M, Liu Y, Gali NK, et al. Aerodynamic analysis of SARS-
392	CoV-2 in two Wuhan hospitals. Nature. 2020.
393	10. Guo ZD, Wang ZY, Zhang SF, Li X, Li L, Li C, et al. Aerosol and Surface Distribution
394	of Severe Acute Respiratory Syndrome Coronavirus 2 in Hospital Wards, Wuhan, China, 2020.
395	Emerg Infect Dis. 2020;26(7).
396	11. Ong SWX, Tan YK, Chia PY, Lee TH, Ng OT, Wong MSY, et al. Air, Surface
397	Environmental, and Personal Protective Equipment Contamination by Severe Acute Respiratory
398	Syndrome Coronavirus 2 (SARS-CoV-2) From a Symptomatic Patient. Jama. 2020.
399	12. Faridi S, Niazi S, Sadeghi K, Naddafi K, Yavarian J, Shamsipour M, et al. A field indoor
400	air measurement of SARS-CoV-2 in the patient rooms of the largest hospital in Iran. Sci Total
401	Environ. 2020;725:138401.
402	13. Chia PY, Coleman KK, Tan YK, Ong SWX, Gum M, Lau SK, et al. Detection of Air and
403	Surface Contamination by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in
404	Hospital Rooms of Infected Patients. medRxiv. [preprint]. In press 2020.
405	14. Davies A, Thomson G, Walker J, Bennett A. A review of the risks and disease
406	transmission associated with aerosol generating medical procedures. J Infect Prev.
407	2009;10(4):122-6.

- 408 15. World Health Organization. Infection prevention and control during health care when
- 409 novel coronavirus (nCoV) infection is suspected Geneva, Switzerland: World Health
- 410 Organization; 2020 [Available from: https://www.who.int/publications-detail/infection-
- 411 prevention-and-control-during-health-care-when-novel-coronavirus-(ncov)-infection-is-

412 <u>suspected-20200125</u>.

- 413 16. Center for Disease Control and Prevention. Healthcare Infection Prevention and Control
- 414 FAQs for COVID-19 Atlanta, United States2020 [updated 20 May 2020. Available from:
- 415 <u>https://www.cdc.gov/coronavirus/2019-ncov/hcp/infection-control-faq.html</u>.
- 416 17. Shiu EYC, Leung NHL, Cowling BJ. Controversy around airborne versus droplet
- 417 transmission of respiratory viruses: implication for infection prevention. Curr Opin Infect Dis.
 418 2019;32(4):372-9.
- 419 18. Tran K, Cimon K, Severn M, Pessoa-Silva CL, Conly J. Aerosol generating procedures
- 420 and risk of transmission of acute respiratory infections to healthcare workers: a systematic421 review. PLOS ONE. 2012.
- 422 19. Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for
- 423 systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol.
- 424 2009;62(10):1006-12.
- 425 20. Kuster SP, Coleman BL, Raboud J, McNeil S, De Serres G, Gubbay J, et al. Risk Factors
 426 for Influenza among Health Care Workers during 2009 Pandemic, Toronto, Ontario, Canada.
 427 Emerging Infectious Diseases. 2013;19(4):606-15.
- 428 21. MacIntyre CR, Seale H, Yang P, Zhang Y, Shi W, Almatroudi A, et al. Quantifying the
- 429 risk of respiratory infection in healthcare workers performing high-risk procedures.
- 430 Epidemiology & Infection. 2014;142:1802-8.
- 431 22. World Health Organization. Infection prevention and control of epidemic- and pandemic-
- 432 prone acute respiratory infections in health care [Internet]. Geneva, Switzerland: World Health
- 433 Organization; 2014 [Available from: <u>https://apps.who.int/iris/handle/10665/112656</u>.
- 434 23. Lynch JB, Davitkov P, Anderson DJ, Bhimraj A, Cheng VC, Guzman-Cottrill J, et al.
- 435 Infectious Diseases Society of America Guidelines on Infection Prevention in Patients with
- 436 Suspected or Known COVID-19 Arlington, United States: IDSA; 2020 [Available from:
- 437 <u>https://www.idsociety.org/practice-guideline/covid-19-guideline-infection-prevention/.</u>
 438 24. Kirkpatrick J, Mitchell C, Taub C, Kort S, Hung J, Swaminathan M. ASE Statement on
- 439 Protection of Patients and Echocardiography Service Providers During the 2019 Novel
- 440 Coronavirus Outbreak 2020 [Available from: https://www.asecho.org/wp-
- 441 content/uploads/2020/03/COVIDStatementFINAL4-1-2020_v2_website.pdf.
- 442 25. Canadian Society of Respiratory Therapists. Position Statement on Procedures Creating a
- 443 Heightened Risk of Infection During an Outbreak of a Communicable Respiratory Disease
- 444 Ottawa, Canada2020 [Available from: <u>https://www.csrt.com/wp-content/uploads/CSRT-</u>
- 445 <u>Procedures-Duringan-Outbreak-April-2020.pdf</u>.
- Thomas P, Baldwin C, Bissett B, boden I, Gosselink R, Granger CL, et al. Physiotherapy
 management for COVID-19 in the acute hospital setting: Recommendations to guide clinical
 practice. 2020.
- 449 27. Alberta Health Services. Aerosol-Generating Medical Procedure Guidance Tool: novel
- 450 coronavirus (COVID-19) Edmonton, Canada: Alberta Health Services; 2020 [Available from: 451 https://www.albertahealthservices.ca/topics/Page17091.aspx.
- 452 28. Ontario Agency for Health Protection and Promotion (Public Health Ontario). Focus on:
- 453 Aerosol generation from coughs and sneezes Toronto, Canada: Queens Printer for Ontario; 2020

- 454 [Available from: <u>https://www.publichealthontario.ca/-/media/documents/ncov/ipac/report-covid-</u>
 455 19-aerosol-generation-coughs-sneezes.pdf?la=en.
- 455 <u>19-aerosoi-generation-coughs-sneezes.pdf/la=en</u>.
- 456 29. Otto S, Babujee A, Neustaedter C, Tschritter D, Saxinger L, McRae A, et al. Among
- 457 countries who are past their initial peak of COVID-19 cases, what proportion of total cases were
- 458 in healthcare workers (HCW), and what is the estimated proportion of the total number of HCWs
- who developed COVID-19 from presumed occupational exposure? COVID-19 Scientific
 Advisory Group Rapid Response Report. [Rapid review]. In press 2020.
- 461 30. Ran L, Chen X, Wang Y, Wu W, Zhang L, Tan X. Risk Factors of Healthcare Workers
- 462 with Corona Virus Disease 2019: A Retrospective Cohort Study in a Designated Hospital of
- 463 Wuhan in China. Clin Infect Dis. 2020.

497 SUPPORTING INFORMATION CAPTIONS

498

500

- 499 A1 Appendix.docx: Additional File 1. Complete Search Strategy
- 501 A2 Appendix.doc: Additional File 2. PRISMA 2009 Checklist

502

503 A3 Appendix.docx: Additional File 3. Table of Excluded Articles